Use of Common Cancer Screenings Rebounded Quickly After Dropping at Start of the Pandemic
March 22, 2021
Screenings for breast cancer and colon cancer dropped dramatically during the early months of the coronavirus pandemic, but use of the procedures returned to near-normal levels by the end of July 2020, according to a new study.
Analyzing insurance claims from more than 6 million Americans with private health coverage, researchers found that mammography rates among women aged 45 to 64 declined by 96% during March and April 2020 as compared to January and February.
Similarly, the weekly rate of colorectal cancer screenings among adults aged 45 to 64 and older declined by 95% during the period.
By the end of July 2020, however, the rate of mammograms among women had rebounded and was slightly higher than it had been before the pandemic was declared. The rate of colonoscopies also rebounded, although it remained below pre-pandemic levels, and did not rebound enough to offset initial reductions in care.
The findings are published online by the Journal of General Internal Medicine.
“These are the first findings to show that, despite real fears about the consequences of drop-off in cancer screens, health facilities figured out how to pick this back up after the initial pandemic restrictions,” said Ryan McBain, the study's lead author and a policy researcher at the RAND Corporation, a nonprofit research organization. “Our study shows that health systems were able to recalibrate resources and protocols in a relatively short interval to deliver these important services.”
Routine cancer screening procedures such as mammography and colonoscopy—essential for early detection and treatment of cancers—rely primarily on office-based medical technologies.
It's been widely known that use of those procedures plummeted immediately after the coronavirus pandemic was declared in March 2020, creating concerns that the trend could delay diagnosis of cancers and as a result have adverse health consequences.
Researchers analyzed medical claims from 6.8 million commercially insured U.S. adults for the period from January 15, 2020 to July 31, 2020. Medical claims data were provided by Castlight Health, a health benefits manager for employer-sponsored health insurance plans across all 50 states. The analysis was limited to those ages 45 to 64—target populations for cancer screening procedures prior to Medicare eligibility.
Prior to the national emergency declaration on March 13, 2020, the median weekly rate of screening mammography was 87.8 women per 10,000 beneficiaries, which declined to 6.9 in April—a 96% drop. By the end of July, the rate of mammograms increased to 88.2 screenings per 10,000 beneficiaries.
In April 2020, colonoscopy screenings declined from 15.1 per 10,000 beneficiaries to 0.9, a 95% difference. The rate of colonoscopies rebounded to 12.6 per 10,000 beneficiaries by the end of July.
“While it is reassuring to see cancer screening rates begin to return to pre-pandemic levels, we have to ensure that people who deferred preventive services are prioritized to get their screening in a timely manner, especially if they are at higher risk of disease,” said Dena M. Bravata, chief medical officer of Castlight Health.
Support for the study was provided by the National Institute on Aging.
Other authors of the study are Jonathan Cantor and Christopher M. Whaley of RAND, Anupam Jena of the Harvard Medical School and Megan F. Pera of Castlight Health.
RAND Health Care promotes healthier societies by improving health care systems in the United States and other countries.